Advances in understanding of toxicities of treatment for head and neck cancer

Oral Oncology

Volumn 45, Issue 10, 2009, Pages 844-848

  Logan, Richard M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Division of Surgical Pathology   (Australia)

Author keywords

Head and neck cancer; Mucositis; Salivary gland hypofunction; Toxicity

Indexed keywords

AMIFOSTINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; FLUOROURACIL; METHOTREXATE; PALIFERMIN; PLACEBO; PLATINUM DERIVATIVE;

ABDOMINAL PAIN; ADD ON THERAPY; ALIMENTARY TRACT MUCOSITIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DIGESTIVE SYSTEM INFLAMMATION; DISEASE SEVERITY; DRUG MEGADOSE; ENTERITIS; ERYTHEMA; GENETIC SUSCEPTIBILITY; GENETICS; HEAD AND NECK CANCER; HUMAN; LARGE INTESTINE MUCOSITIS; LOW DRUG DOSE; MUCOSA INFLAMMATION; NONHUMAN; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PATHOLOGY; PRIORITY JOURNAL; RADIATION HAZARD; REVIEW; RISK FACTOR; SALIVARY GLAND DISEASE; SALIVARY GLAND HYPOFUNCTION; SKIN TOXICITY; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE; TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; ULCER;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MUCOSITIS; MUCOUS MEMBRANE; RADIATION INJURIES; RISK FACTORS; SALIVARY GLANDS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 70349120913     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.03.018     Document Type: Review

References (51)

1. Haddad R.I., and Shin D.M. Recent advances in head and neck cancer. N Engl J Med 359 11 (2008) 1143-1154
2. Bellm L.A., Epstein J.B., Rose-Ped A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 8 1 (2000) 33-39
3. Elting L.S., Keefe D.M., Sonis S.T., Garden A., Spijkervet F.K., Barasch A., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 113 (2008) 2704-2713
4. Elting L.S., Cooksley C., Chambers M.S., Cantor S.B., Manzullo E., and Rubenstein E.B. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (2003) 1531-1539
5. Nonzee N.J., Dandade N.A., Markossian T., Agulnik M., Argiris A., Patel J.D., et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. Cancer 113 6 (2008) 1446-1452
6. Scully C., and Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 45 4-5 (2009) 301-308
7. Gold K.A., Lee H.-Y., and Kim E.S. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 9999 9999 (2009) NA
8. Rapidis A.D., Trichas M., Stavrinidis E., Roupakia A., Ioannidou G., Kritselis G., et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol 42 7 (2006) 675-684
9. Pignon J.P., Bourhis J., Domenge C., and Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 9208 (2000) 949-955
10. Pignon J.-.P., le Maitre A., and Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol, Biol, Phys 69 2 (2007) S112-S114
11. Scher R., and Esclamado R. Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. Semin Rad Oncol 19 (2009) 17-23
12. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol: J Eur Soc Therap Radiol Oncol 85 1 (2007) 156-170
13. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Rad Oncol 19 (2009) 3-10
14. Pico J.-.L., Avila-Garavito A., and Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3 (1998) 446-451
15. Keefe D.M.K., Brealey J., Goland G.J., and Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47 5 (2000) 632-637
16. Vera-Llonch M., Oster G., Hagiwara M., and Sonis S.T. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106 2 (2006) 329-336
17. Trotti A., Bellm L.A., Epstein J.B., Frame D., Fuchs H.J., Gwede C.K., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 3 (2003) 253-262
18. Rubenstein E.B., Peterson D., Schubert M., Keefe D.M.K., McGuire D., Epstein J., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 S9 (2004) 2026-2046
19. Wolff H., Overbeck T., Roedel R., Hermann R., Herrmann M., Kertesz T., et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol (1999)
20. Harari P.M., Wheeler D.L., and Grandis J.R. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 19 1 (2009) 63-68
21. Lorch J.H., Posner M.R., Wirth L.J., and Haddad R.I. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol 45 4-5 (2009) 447-453
22. Dietz A., Boehm A., Mozet C., Wichmann G., and Giannis A. Current aspects of targeted therapy in head and neck tumors. Eur Arch Oto-Rhino-Laryngol 265 (2008) 3-12
23. Langer C. Targeted therapy in head and neck cancer. Cancer 112 12 (2008) 2635-2645
24. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
25. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus Cetuximab in head and neck cancer. N Engl J Med 359 11 (2008) 1116-1127
26. Bernier J., Bonner J., Vermorken J.B., Bensadoun R.J., Dummer R., Giralt J., et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19 1 (2008) 142-149
27. Pryor D.I., Porceddu S.V., Burmeister B.H., Guminski A., Thomson D.B., Shepherdson K., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 2 (2009) 172-176
28. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 23 34 (2005) 8646-8654
29. Keefe D., Schubert M., Elting L., Sonis S., Epstein J., Raber-Durlacher J., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109 5 (2007) 820-831
30. van der Velden W.J.F.M., Herbers A.H.E., and Blijlevens N.M.A. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplant 43 1 (2008) 85-86
31. Scully C., Epstein J., and Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1: Pathogenesis and prophylaxis of mucositis. Head Neck 25 12 (2003) 1057-1070
32. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 20 1 (2004) 11-15
33. Sonis S.T. A biological approach to mucositis. J Support Oncol 2 (2004) 21-36
34. Logan R., Stringer A., Bowen J., Gibson R., Sonis S., and Keefe D. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemother Pharmacol 63 2 (2009) 239-251
35. Logan R.M., Gibson R.J., Bowen J.M., Stringer A.M., Sonis S.T., and Keefe D.M.K. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62 1 (2008) 33-41
36. Stringer A., Gibson R.J., Logan R., Bowen J.M., Yeoh A.S.J., Hamilton J., et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Proc Soc Exp Biol Med (2009) 0810-RM-0301
37. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., et al. American Society of Clinical Oncology 2008. Clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 1 (2009) 127-145
38. Keefe D.M., Sonis S.T., and Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs 13 3 (2008) 511
39. Brosky M. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol 5 5 (2007) 215-225
40. Shiboski C.H., Hodgson T.A., Ship J.A., and Schiødt M. Management of salivary hypofunction during and after radiotherapy. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endodontol 103 Suppl. 1 (2007) S66.e19-S66.e61
41. Al-Qahtani K., Hier M.P., Sultanum K., and Black M.J. The role of submandibular salivary gland transfer in preventing xerostomia in the chemoradiotherapy patient. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endodontol 101 6 (2006) 753-756
42. Teymoortash A., Müller F., Juricko J., Bieker M., Mandic R., Librizzi D., et al. Botulinum toxin prevents radiotherapy-induced salivary gland damage. Oral Oncol 45 8 (2009) 737-739
43. Lombaert I., Brunsting J., PK W., Kampinga H., de Haan G., and Coppes R.P. Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of stem/progenitor pool. Stem Cells 26 10 (2008) 2595-2601
44. Miaskowski C., Aouizerat B.E., Dodd M., and Cooper B. Conceptual Issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr 2007 37 (2007) 39-46
45. Aprile G., Ramoni M., Keefe D., and Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112 2 (2008) 284-292
46. Dean-Colomb W., and Esteva F.J. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44 18 (2008) 2806-2812
47. Efferth T., and Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Therap 107 2 (2005) 155-176
48. Barnett G.C., West C.M.L., Dunning A.M., Elliott R.M., Coles C.E., Pharoah P.D.P., et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 9 2 (2009) 134-142
49. Huang R.S., and Ratain M.J. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 59 1 (2009) 42-55
50. Kweekel D., Guchelaar H.-.J., and Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34 7 (2008) 656-669
51. Buur van Kooten Niekerk P., Schmiegelow K., and Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 81 5 (2008) 391-398